UPDATE: Noble Financial Starts Peregrine Pharmaceuticals (PPHM) at Buy; Positive on Phosphatidylserine Potential

Go back to UPDATE: Noble Financial Starts Peregrine Pharmaceuticals (PPHM) at Buy; Positive on Phosphatidylserine Potential

Peregrine Pharma (PPHM) Tops Q4 EPS by 1c

July 14, 2015 4:06 PM EDT

Peregrine Pharma (NASDAQ: PPHM) reported Q4 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $9.31 million versus the consensus estimate of $6.42 million.

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.

... More